Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PF-06669571 in Healthy Subjects
NCT02184429Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06669571 in Parkinson's disease (PD) (7 cohorts), sponsored by Pfizer. Primary endpoint: Columbia Suicide Severity Rating Scale at Day 28. Started Jul 2014; status: completed.
02
Drugs
PF-06669571
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02184429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02184429.